Financing And Funding Gap For 16 Vaccines Across 94 Low- And Middle-Income Countries, 2011–30

Sriudomporn, Salin; Sim, So Yoon; Mak, Joshua; Brenzel, Logan; Patenaude, Bryan

doi:10.1377/hlthaff.2022.00343

Cited by 5 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous work has sought to track development assistance for health [ 18 ], maternal, newborn, and child health [ 19 ], and immunisation [ 12 , 20 , 21 ]. These tracking exercises were based primarily on the OECD Creditor Reporting System and measured past donor finance over time, or project future financing based on these data [ 21 ]. Our approach, which focuses on current donor financing, is novel.…”

Section: Discussionmentioning

confidence: 99%

Recovery of Routine Immunisation: Mapping External Financing Opportunities for Reaching Zero-Dose Children

Tougher¹,

Mandalia

Griffiths

2023

Vaccines

View full text Add to dashboard Cite

The COVID-19 pandemic has precipitated large declines in childhood vaccination coverage and, consequently, substantial increases in the number of zero-dose children. To effectively respond to these declines, it is necessary to direct resources for recovery. We mapped active external financing for immunisation and primary healthcare in 20 countries with the highest numbers of zero-dose children to promote transparency and donor coordination. We found that countries have disparate access to external financing, with the two upper-middle-income countries (Brazil and Mexico) only having access to loans from the International Bank for Reconstruction and Development. Domestic resource mobilization is, therefore, key in these two countries, although fiscal space is likely constrained. Four additional countries (Angola, Indonesia, Philippines, and Vietnam) do not have allocations from Gavi, the Vaccine Alliance for Health Systems Strengthening, or Equity Accelerator Funding, but are eligible for support under Gavi’s Middle-Income Countries Approach. Our methods, which focus on current donor financing, are novel and reveal substantial variations in access to external financing to support immunisation in high-burden countries. The available data differ considerably across financing mechanisms, making it difficult to synthesise the results across funding sources.

show abstract

Section: Discussionmentioning

confidence: 99%

Recovery of Routine Immunisation: Mapping External Financing Opportunities for Reaching Zero-Dose Children

Tougher¹,

Mandalia

Griffiths

2023

Vaccines

View full text Add to dashboard Cite

show abstract

“…Many low- and middle-income countries (LMICs) have limited access to some vaccines and therapeutics [ 78 – 80 ]. Limited access to healthcare and vaccination may also lead to epidemics and outbreaks in such low-income regions [ 81 ].…”

Section: Preparedness Against Invasive Meningococcal Diseasementioning

confidence: 99%

“…Limited access to healthcare and vaccination may also lead to epidemics and outbreaks in such low-income regions [ 81 ]. Meningococcal vaccination in LMICs may only be available through external support, such as Gavi, the Vaccine Alliance, to fund purchases of vaccines [ 78 , 80 ]. In a systematic review describing investment cases for vaccines and immunization programs, the authors reported that the investment cases identified research and development gaps in LMICs, including the need for funds to support clinical trials and purchases of vaccines [ 82 ].…”

Section: Preparedness Against Invasive Meningococcal Diseasementioning

confidence: 99%

“…In a systematic review describing investment cases for vaccines and immunization programs, the authors reported that the investment cases identified research and development gaps in LMICs, including the need for funds to support clinical trials and purchases of vaccines [ 82 ]. The withdrawal of Gavi support in LMICs transitioning to fully self-financing may potentially lead to additional funding gaps experienced by some countries [ 80 ].…”

Section: Preparedness Against Invasive Meningococcal Diseasementioning

confidence: 99%

See 1 more Smart Citation

Meningococcal Disease in the Post–COVID-19 Era: A Time to Prepare

Bloom,

Bonanni,

Martinón-Torres

et al. 2023

Infect Dis Ther

View full text Add to dashboard Cite

The global invasive meningococcal disease (IMD) landscape changed considerably during the COVID-19 pandemic, as evidenced by decreased incidence rates due to COVID-19 mitigation measures, such as limited social contact, physical distancing, mask wearing, and hand washing. Vaccination rates were also lower during the pandemic relative to pre-pandemic levels. Although policymakers may have shifted their focus away from IMD vaccination programs to COVID-19 vaccination programs, strong arguments support implementation and prioritization of IMD vaccination programs; IMD cases have increased in some countries and IMD rates may even have exceeded pre-pandemic levels. Additional concerns include increased susceptibility due to vaccination coverage gaps, increased incidence of other respiratory pathogens, immunity debt from lockdown restrictions, and increased IMD epidemiologic variability. The full range of benefits of widely available and effective meningococcal vaccines needs to be considered, especially in health technology assessments, where the broad benefits of these vaccines are neither accurately quantified nor captured in implementation policy decisions. Importantly, implementation of meningococcal vaccination programs in the current IMD climate also appeals to broader healthcare principles, including preparedness rather than reactive approaches, generally accepted benefit–risk approaches to vaccination, historical precedent, and the World Health Organization's goal of defeating meningitis by 2030. Countries should therefore act swiftly to bolster existing meningococcal vaccination strategies to provide broad coverage across age groups and serogroups given the recent increases in IMD incidence.

show abstract

The Impact of Vaccination on COVID-19, Influenza, and Respiratory Syncytial Virus-Related Outcomes: A Narrative Review

Debbag,

Rudin,

Ceddia

et al. 2024

Infect Dis Ther

View full text Add to dashboard Cite

Financing And Funding Gap For 16 Vaccines Across 94 Low- And Middle-Income Countries, 2011–30

Cited by 5 publications

References 9 publications

Recovery of Routine Immunisation: Mapping External Financing Opportunities for Reaching Zero-Dose Children

Recovery of Routine Immunisation: Mapping External Financing Opportunities for Reaching Zero-Dose Children

Meningococcal Disease in the Post–COVID-19 Era: A Time to Prepare

The Impact of Vaccination on COVID-19, Influenza, and Respiratory Syncytial Virus-Related Outcomes: A Narrative Review

Contact Info

Product

Resources

About